The WHO learned to love ‘anti-obesity’ jabs in 2025. I don’t fully agree, but I get it | Devi Sridhar
While GLP-1 drugs promise an easy fix, our bodies still need what they have always needed: healthy food and regular exercise Prof Devi Sridhar is chair of global public health at the University of Edinburgh If there has been a hot topic in health in 2025, it’s definitely been GLP-1s, colloquially referred to as “anti-obesity” […]
Novo and Lilly Cut Prices Of Weight-loss Drugs in China
Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China, according to the Danish drugmaker and Chinese drug… Reuters Health Information
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
Metabolic dysfunction-associated steatohepatitis (MASH) is a multifactorial metabolic liver disease that occurs in the context of obesity, insulin resistance and cardiometabolic comorbidities. Monotherapy targeting single pathways often provides only partial improvements in histological liver fibrosis and systemic metabolic parameters, prompting growing interest in multitargeted combination therapies. Multitargeted and combination strategies for MASH can modulate multiple […]
Ozempic is changing more than weight: New global research shows how GLP-1 drugs are reshaping self and society, identity and mental health, not just bodies. Much of the demand is driven by weight anxiety, even among medically “healthy” users. Many users endure severe side effects and high costs.
submitted by /u/mvea [link] [comments]
GLP-1 psychological side effects: a psychiatrist’s view
As a physician-psychiatrist, I have watched the rise of GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) with genuine admiration. They are transforming metabolic health, reducing cardiovascular risk, and offering hope to patients who have struggled for decades. For many, these medications are lifesaving. But alongside the excitement, I’m witnessing something rarely discussed: a change in personality […]
What to know as first FDA-approved GLP-1 pill for weight loss heads for pharmacies
The FDA has approved the first GLP-1 pill for weight loss and it’s expected in pharmacies in the coming weeks. Dr. Holly Lofton, director of the Medical Weight Management Program at NYU Langone, joins CBS News to discuss. CBS News 24/7 is the premier anchored streaming news service from CBS News and Stations that is […]
6 new care and payment models CMS introduced in 2025
CMS introduced several new care and payment models in 2025, many focused on drug pricing, chronic disease management and prevention: 1. CMS published plans Dec. 23 for its voluntary “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth” — or BALANCE — model. Under the model, CMS will negotiate reduced prices with GLP-1 manufacturers for […]
Can Amgen’s MariTide Take on Leaders in the Obesity Space?
Amgen AMGN is one of the few companies with a late-stage obesity candidate in its pipeline. The company is developing MariTide, an investigational GLP-1/GIP receptor agonist, as part of its comprehensive MARITIME phase III program in obesity. With this drug, Amgen intends to take on Eli Lilly LLY and Novo Nordisk NVO, which currently dominate […]
Obesity efforts dominate dealmaking in 2025
When glucagon-like peptide-1 (GLP-1) receptor agonists entered the market for obesity and overweight indications in recent years, the uptake and enthusiasm drove investor excitement for companies advancing any of the new mechanisms in the space.
Tirzepatide noninferior to dulaglutide for CV outcomes in type 2 diabetes
Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial infarction, or stroke among patients with type 2 diabetes and atherosclerotic CV disease, according to a study published in the Dec. 18/25 issue of the New England Journal of Medicine.